Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________to ___________

Commission File Number: 333-251016

CANNAPHARMARX, INC.

(Exact name of small business issuer as specified in its charter)

Delaware		27-4635140
(State of other jurisdiction of incorporation)		(IRS Employer ID No.)

Suite 3600

888 – 3^rd Street SW

Calgary, Alberta, Canada T2P 5C5

(Address of principal executive offices)

949-652-6838

(Issuer’s Telephone Number)

Securities registered pursuant to Section 12(b) of the Act:

None

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CPMD	OTC Pink Sheets

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. ☐ Yes ☒ No

The number of shares of the registrant’s common stock issued and outstanding as of November 16, 2023, was 337,961,136 shares.

CANNAPHARMARX, INC.

SEPTEMBER 30, 2023

(UNAUDITED)

TABLE OF CONTENTS

		Page

	PART I. FINANCIAL INFORMATION

Item 1	Financial Statements (unaudited)	3
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations/Plan of Operation	22
Item 3	Quantitative and Qualitative Disclosures About Market Risk	28
Item 4	Controls and Procedures	28

	PART II. OTHER INFORMATION

Item 1	Legal Proceedings	29
Item 1A	Risk Factors	29
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3	Defaults Upon Senior Securities	30
Item 4	Mine Safety Disclosures	30
Item 5	Other Information	30
Item 6	Exhibits	30
	Signatures	31

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CANNAPHARMAX, INC.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS

(Unaudited)



	September 30, 2023			December 31, 2022

ASSETS

Current assets
Cash	$	–		$	2,317
HST receivable		54,318			23,251
Prepaid expense		–			68,539
Other assets		–			5,907
Total current assets		54,318			100,014

Non-current assets
Property, plant and equipment, net		167,483			107,780
Right-of-use building, net		4,934,188			5,127,622
Investments		–			78,760
Total assets	$	5,155,989		$	5,414,176

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities
Bank overdraft	$	245		$	–
Accounts payable and accrued liabilities		7,772,254			6,882,947
Accrued interest		405,356			151,925
Accrued legal settlement		190,000			190,000
Notes payable		7,867,828			7,715,858
Convertible notes - net of discount		1,379,252			1,141,060
Derivative liability		906,946			1,008,868
Loan payable - related party		1,519,018			74,497
Liability for right-of-use building, current portion		187,793			260,432
Total current liabilities		20,228,692			17,425,587

Non-current liability
Liability for right-of-use building		5,557,272			5,333,045
Total liabilities	$	25,785,964		$	22,758,632

Commitments and contingencies		–			–

STOCKHOLDERS’ DEFICIT
Preferred stock, Series A, $1.00 par value, 100,000 shares authorized, 84,416 and 84,416 shares issued and outstanding as at September 30, 2023 and December 31, 2022, respectively	$	84,416		$	84,416
Preferred Stock Series B, $1.00 par value, 3,000,000 shares authorized, 2,455,000 and 2,475,000 shares issued and outstanding as at September 30, 2023 and December 31, 2022, respectively		2,455,000			2,475,000
Common stock, $0.0001 par value; 5,000,000,000 shares authorized, 294,764,614 and 274,124,622 issued and outstanding as at September 30, 2023 and December 31, 2022, respectively		29,476			27,412
Treasury stock, 6,230,761 and 133,200 shares as at September 30, 2023 and December 31, 2022, respectively		597			(13	)
Additional paid-in capital		75,247,742			74,523,642
Accumulated deficit		(98,551,864	)		(94,695,339	)
Accumulated other comprehensive income		104,658			240,426
Total stockholders’ deficit		(20,629,975	)		(17,344,456	)
Total liabilities and stockholders’ deficit	$	5,155,989		$	5,414,176

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

CANNAPHARMAX, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS

(Unaudited)


	Three months ended September 30,						Nine months ended September 30,
	2023			2022			2023			2022

Revenue	$	–		$	–		$	–		$	–

Operating expenses
General and administrative		336,620			201,818			857,573			511,067
Amortization and depreciation		76,550			75,972			223,904			221,589
Stock-based compensation		45,245			45,245			135,734			135,734
Rent		12			3,038			2,615			12,477
Professional fees		44,778			97,016			241,113			439,078
Payroll and consulting fees		164,292			165,386			819,774			688,228
Total operating expenses		667,497			588,475			2,280,713			2,008,173
Loss from operations		(667,497	)		(588,475	)		(2,280,713	)		(2,008,173	)

Other income (expenses)
Interest expense		(354,862	)		(441,673	)		(1,169,502	)		(1,443,204	)
Loss on the extinguishment of debt		–			(203,130	)		(429,471	)		(713,786	)
Loss on investments		–			–			(78,760	)		–
Change in the fair value of derivative liability		457,991			(79,970	)		101,921			(726,396	)
Total other income (expenses), net		103,129			(724,773	)		(1,575,812	)		(2,883,386	)
Net loss	$	(564,368	)	$	(1,313,248	)	$	(3,856,525	)	$	(4,891,559	)
Foreign currency translation adjustment		33,132			528,940			(135,768	)		678,194
Net comprehensive loss	$	(531,236	)	$	(784,308	)	$	(3,992,293	)	$	(4,213,365	)

Basic and diluted loss per common share	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.02	)

Weighted average number of shares outstanding		295,096,003			241,098,037			292,670,792			197,052,865

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

CANNAPHARMAX, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS

(Unaudited)


	Nine months ended September 30,
	2023			2022

Operating activities
Net loss	$	(3,856,525	)	$	(4,891,559	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation		223,904			221,589
Stock-based compensation		135,734			135,734
Interest expense		1,169,502			1,443,204
Loss on extinguishment of debt		429,471			713,786
Loss on investments		78,760			–
Change in the fair value of derivative liability		(101,921	)		726,396
Changes in operating assets and liabilities:
HST receivable		(31,067	)		(15,233	)
Prepaid expenses		68,539			(71,746	)
Other assets		5,907			(5,837	)
Accounts payable and accrued liabilities		765,295			1,875,820
Cash overdraft		245			–
Accrued interest		142,124			(739,039	)
Subscription liability		–			249,991
Net cash used in operating activities		(970,032	)		(356,894	)

Investing activity
Purchases of property, plant and equipment		(78,880	)		(106,886	)
Net cash used in investing activity		(78,880	)		(106,886	)

Financing activities
Proceeds from convertible notes		213,750			694,950
Proceeds from loans payable – related party		1,412,227			74,714
Repayment of promissory notes		–			(596,012	)
Proceeds from issuance of Series B preferred shares		–			55,989
Proceeds from issuance of common stock in private placements		–			290,012
Proceeds from commitment shares issued with convertible notes		–			17,000
Proceeds from commitment shares issued for equity line of credit		–			130,000
Proceeds from beneficial conversion feature of convertible notes		–			345,551
Payments made on liability for right-of-use building		(579,382	)		(568,689	)
Net cash provided by financing activities		1,046,595			443,515

Net change in cash		(2,317	)		(20,265	)
Cash, beginning of period		2,317			27,767
Cash, end of period	$	–		$	7,502

Supplemental disclosure of cash flow information:
Cash paid for interest	$	–		$	–

Supplemental disclosure of non-cash flow investing and financing activities:
Acquisition of right-of-use assets for lease obligations	$	–		$	5,727,811
Stock issued as a financing expense on convertible notes	$	–		$	147,000
Preferred stock issued as a deposit on an acquisition	$	–		$	55,989
Common stock issued to convert convertible notes and accrued interest into equity	$	138,881		$	1,180,269

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

CANNAPHARMAX, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(Unaudited)


	Preferred Stock Series A			Preferred Stock Series B					Common Stock					Treasury Stock				Additional					Accumulated
	Number			Number					Number					Number				Paid					Other
	of Shares	Value		of Shares		Value			of Shares		Value			of Shares	Value			in Capital		Accumulated Deficit			Comprehensive Income			Deficit
Balance, December 31, 2022	84,416	$	84,416	2,475,000		$	2,475,000		274,124,622		$	27,412		133,200	$	(13	)	$	74,523,642	$	(94,695,339	)	$	240,426		$	(17,344,456	)
Conversion of Series B to common stock	–		–	(20,000	)		(20,000	)	20,000			2		–		–			19,998		–			–			–
Conversion of convertible notes to common stock	–		–	–			–		20,619,992			2,062		–		–			504,953		–			–			507,015
Stock-based compensation	–		–	–			–		–			–		–		–			45,245		–			–			45,245
Foreign currency translation adjustment	–		–	–			–		–			–		–		–			–		–			(5,656	)		(5,656	)
Net loss	–		–	–			–		–			–		–		–			–		(1,412,573	)		–			(1,412,573	)
Balance, March 31, 2023	84,416	$	84,416	2,455,000		$	2,455,000		294,764,614		$	29,476		133,200	$	(13	)	$	75,093,838	$	(96,107,912	)	$	234,770		$	(18,210,425	)
Conversion of convertible notes to common stock	–		–	–			–		6,097,561			610		–		–			63,415		–			–			64,025
Stock-based compensation	–		–	–			–		–			–		–		–			45,244		–			–			45,244
Foreign currency translation adjustment	–		–	–			–		–			–		–		–			–		–			(163,244	)		(163,244	)
Net loss	–		–	–			–		–			–		–		–			–		(1,879,584	)		–			(1,879,584	)
Balance, June 30, 2023	84,416	$	84,416	2,455,000		$	2,455,000		300,862,175		$	30,086		133,200	$	(13	)	$	75,202,497	$	(97,987,496	)	$	71,526		$	(20,143,984	)
Common stock returned to treasury	–		–	–			–		(6,097,561	)		(610	)	6,097,561		610			–		–			–			–
Stock-based compensation	–		–	–			–		–			–		–		–			45,245		–			–			45,245
Foreign currency translation adjustment	–		–	–			–		–			–		–		–			–		–			33,132			33,132
Net loss	–		–	–			–		–			–		–		–			–		(564,368	)		–			(564,368	)
Balance, September 30, 2023	84,416	$	84,416	2,455,000		$	2,455,000		294,764,614		$	29,476		6,230,761	$	597		$	75,247,742	$	(98,551,864	)	$	104,658		$	(20,629,975	)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

CANNAPHARMAX, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (continued)

(Unaudited)

	Preferred Stock Series A					Preferred Stock Series B			Common Stock			Treasury Stock				Additional					Accumulated
	Number of					Number of			Number of			Number of				Paid in		Accumulated			Other Comprehensive
	Shares		Value			Shares	Value		Shares	Value		Shares	Value			Capital		Deficit			Loss			Deficit
Balance, December 31, 2021	67,191		$	67,191		475,000	$	475,000	125,509,810	$	12,551	133,200	$	(13	)	$	73,055,579	$	(86,164,319	)	$	(371,909	)	$	(12,925,920	)
Conversion of Series A to common stock	(9,011	)		(9,011	)	–		–	11,263,750		1,126	–		–			7,885		–			–			–
Conversion of convertible notes to common stock	–			–		–		–	28,186,741		2,819	–		–			499,096		–			–			501,915
Sale of common stock in private placement	–			–		–		–	2,500,000		250	–		–			39,765		–			–			40,015
Commitment shares issued with convertible note	–			–		–		–	1,000,000		100	–		–			16,900		–			–			17,000
Beneficial conversion feature of convertible notes	–			–		–		–	–		–	–		–			227,386		–			–			227,386
Stock-based compensation related to warrant issuances	–			–		–		–	–		–	–		–			45,245		–			–			45,245
Foreign currency translation adjustment	–			–		–		–	–		–	–		–			–		–			(120,750	)		(120,750	)
Net loss	–			–		–		–	–		–	–		–			–		(2,071,982	)		–			(2,071,982	)
Balance, March 31, 2022	58,180		$	58,180		475,000	$	475,000	168,460,301	$	16,846	133,200	$	(13	)	$	73,891,856	$	(88,236,301	)	$	(492,659	)	$	(14,287,091	)
Conversion of convertible notes to common stock	–			–		–		–	23,987,460		2,398	–		–			327,201		–			–			329,599
Sale of common stock in private placement	–			–		–		–	25,000,000		2,500	–		–			247,497		–			–			249,997
Commitment shares issued for equity line of credit	–			–		–		–	10,000,000		1,000	–		–			129,000		–			–			130,000
Beneficial conversion feature of convertible notes	–			–		–		–	–		–	–		–			64,414		–			–			64,414
Stock-based compensation related to warrant issuances	–			–		–		–	–		–	–		–			45,245		–			–			45,245
Foreign currency translation adjustment	–			–		–		–	–		–	–		–			–		–			270,004			270,004
Net loss	–			–		–		–	–		–	–		–			–		(1,506,329	)		–			(1,506,329	)
Balance, June 30, 2022	58,180		$	58,180		475,000	$	475,000	227,447,761	$	22,744	133,200	$	(13	)	$	74,705,213	$	(89,742,630	)	$	(222,655	)	$	(14,704,161	)

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

CANNAPHARMAX, INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (continued)

(Unaudited)

	Preferred Stock Series A					Preferred Stock Series B			Common Stock					Treasury Stock				Additional						Accumulated Other
	Number					Number			Number					Number				Paid						Comprehensive
	of Shares		Value			of Shares	Value		of Shares		Value			of Shares	Value			in Capital			Accumulated Deficit			Income (Loss)			Deficit
Balance, June 30, 2022	58,180		$	58,180		475,000	$	475,000	227,447,761		$	22,744		133,200	$	(13	)	$	74,705,213		$	(89,742,630	)	$	(222,655	)	$	(14,704,161	)
Conversion of convertible notes to common stock	–			–		–		–	22,916,415			2,292		–		–			346,463			–			–			348,755
Conversion of Series A Preferred to common stock	(13,764	)		(13,764	)	–		–	17,205,000			1,721		–		–			12,044			–			–			1
Conversion of common shares issued for equity line of credit to Series A Preferred	8,000			8,000		–		–	(10,000,000	)		(1,000	)	–		–			(7,000	)		–			–			–
Issuance of Series B Preferred for deposit on acquisition	–			–		2,000,000		2,000,000	–			–		–		–			(1,944,011	)		–			–			55,989
Beneficial conversion feature of convertible notes	–			–		–		–	–			–		–		–			53,750			–			–			53,750
Stock based compensation related to warrant issuances	–			–		–		–	–			–		–		–			45,245			–			–			45,245
Foreign currency translation adjustment	–			–		–		–	–			–		–		–			–			–			528,940			528,940
Net loss	–			–		–		–	–			–		–		–			–			(1,313,248	)		–			(1,313,248	)
Balance September 30, 2022	52,416		$	52,416		2,475,000	$	2,475,000	257,569,176		$	25,757		133,200	$	(13	)	$	73,211,704		$	(91,055,878	)	$	306,285		$	(14,984,729	)

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

CannaPharmaRX (“CPRX” or the “Company”) was originally incorporated in the state of Colorado in August 1998 as Network Acquisitions, Inc. The Company focuses its business efforts on evaluation, negotiation, acquisition, and development cannabis cultivation projects in Canada.

On January 6, 2022, the Company entered into a 20-year operating lease with Formosa Mountain Ltd. for the use of a leased facility located in Cremona, Alberta, Canada. The facility was built in 2015 and was previously operating as a cannabis production facility until it was decommissioned, and the license cancelled by the previous owner making the facility ready for sale in 2020.

CPRX recommissioned the 55,000 square foot facility which contains 11 growing rooms and 10 drying and packing rooms into a new indoor cannabis farm during 2022. The Company received an operating license from Health Canada on December 9, 2022, and a cannabis license from the Canada Revenue Agency (“CRA”) on December 22, 2022.

On February 21, 2023, the Company entered into a supply agreement with Y.S.A. Holdings Ltd (“Y.S.A.”), an Israeli corporation, whereby the Company will supply 450kg of cannabis biomass in the form of dried flowers and dried trim per annum to Y.S.A over a two-year period. No biomass has been delivered to Y.S.A as at the date of this Report.

Under the new license the date of the first and second harvest were August 10, 2023 and September 11, 2023 respectively. The first and second harvest yielded saleable cannabis flower product of approximately 75 kilograms (“kg”) and 120 kg respectively.

Preliminary discussions with export partners would set conditional per gram pricing at approximately $3.30 Canadian dollars (“CAD”) per gram. This price would be based on achieving satisfactory test results associated to tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) content of the dried flower.

Basis of presentation

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standard Codification, the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”).

All figures are in United States (“US”) dollars (“USD”) unless indicated otherwise.

Use of estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates relate to the purchase price allocation of acquired businesses, the impairment of long-lived assets, the valuation of financial instruments, the provision of income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as at the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Cash

The Company considers all its cash in bank accounts and its highly liquid temporary cash investments with an original maturity of three months or less to be cash and cash equivalents. On September 30, 2023, the Company had cash of $nil (December 31, 2022 - cash of $2,317).0

Comprehensive income or loss

ASC 220 Comprehensive Income establishes standards for the reporting and display of comprehensive income and its components in the financial statements. As at September 30, 2023, and December 31, 2022, the Company determined that it had items that represented components of comprehensive income and therefore has included a statement of comprehensive income in the financial statements.

Reclassifications

Certain prior-year amounts have been reclassified to conform to the current-period presentation. These reclassifications had no impact on net earnings and the Company’s financial position.

Leases

The Company recognizes right-of-use assets and corresponding liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised as either operating or finance leases at the inception of an agreement where it is determined that a lease exists. This classification of operating or finance lease determines the presentation of corresponding expenses over the lifetime of the lease.

Finance lease assets represent the right to use an underlying asset for the lease term, and finance lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are recognized based on the present value of future payments over the lease term at commencement date. A collateralized incremental borrowing rate based on the information available at commencement date, including lease term, is used in determining the present value of future payments. This incremental borrowing rate is updated in the event of a lease modification such as a renewal or option that adds time and payments to a lease. A lease term generally does not include an option to extend or terminate the lease, unless there is a reasonable certainty that the option will be exercised. Fixed payments may contain predetermined fixed rent escalations. The Company recognizes the expense related to finance leases using the effective interest rate method from the commencement date to the end of the lease term. Certain lease contracts contain non-lease components such as maintenance, utilities, fuel and other services. The Company recognizes both the lease and non-lease component for each right-of-use asset.

Short-term leases (that have an initial term less than 12 months or that are cancellable by the lessor and lessee without significant penalties) are expensed as they are incurred.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Derivative financial instruments

Terms of convertible and other promissory notes are reviewed to determine whether they contain embedded derivative instruments that are required to be accounted for separately from the host contract and recorded on the balance sheet at fair value. The fair value of derivative instruments is required to be revalued at each reporting date, with corresponding changes in fair value recorded in the current period operating results. Derivative liabilities arose due to the issuance of variably priced convertible notes. For the period ended September 30, 2023, the Company had derivative liabilities of $906,946 (December 31, 2022 - $1,008,868).

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk.

Foreign currency translation

The functional currency and the reporting currency of the Company’s US operations is USD. The functional currency of the Company’s Canadian operations is CAD. Management adopted ASC 830 Foreign Currency Matters for transactions that occur in foreign currencies. Monetary assets denominated in foreign currencies are translated using the exchange rate prevailing at the balance sheet date. Average monthly rates are used to translate revenues and expenses.

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income for the respective periods.

Assets and liabilities of the Company’s operations are translated into the reporting currency, USD, at the exchange rate in effect at the balance sheet dates. Revenue and expenses are translated at average rates in effect during the reporting periods. Equity transactions are recorded at the historical rate when the transaction occurred. The resulting translation adjustment is reflected as accumulated other comprehensive income, a separate component of stockholders' equity in the statement of stockholders' equity. These translation adjustments are reflected in accumulated other comprehensive income, a separate component of the Company's stockholders' equity.

Harmonized sales tax

The Harmonized Sales Tax (“HST”) is a combination of the Canadian Goods and Services Tax (“GST”) and Provincial Sales Tax (“PST”) that is applied to taxable goods and services. HST is a consumption tax paid by the consumer at the point of sale (POS). The vendor or seller collects the tax proceeds from consumers by adding the HST rate to the cost of goods and services. They then remit the total collected tax, less input tax credits for HST paid to vendors, to the government periodically.

The HST is in effect in five of the ten Canadian provinces: New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, and Prince Edward Island. The HST is collected by the CRA, which remits the appropriate amounts to the participating provinces. The HST may differ across these five provinces, as each province will set its own PST rates within the HST. In provinces and territories which have not enacted the HST, the CRA collects only the 5% goods and services tax. The current rate in Ontario is 13%.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

Stock-based compensation

The Company has adopted ASC Topic 718 Compensation - Stock Compensation, which establishes a fair value method of accounting for stock-based compensation plans. In accordance with guidance now incorporated in ASC Topic 718, the fair value of stock options and warrants issued to employees and non-employees is measured on the grant date based on the fair value. The fair value is determined using the Black-Scholes option pricing model. The resulting amount is charged to expense on a straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period. The fair value of share purchase warrants was determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires management to make various estimates and assumptions, including expected term, expected volatility, risk-free rate, and dividend yield. The Company had no stock options outstanding as at September 30, 2023 or December 31, 2022.

Long-lived assets

The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value.

Fair values of assets and liabilities

The Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded, and the reliability of the assumptions used to determine fair value.

Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (continued)

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Financial instruments

The estimated fair value for financial instruments was determined at discrete points in time based on relevant market information. These estimates involve uncertainties and could not be determined with exact precision. The fair value of the Company’s financial instruments, which include cash, prepaid expenses, accounts payable, and the related party loan, each approximate their carrying value due either to their short length to maturity or interest rates that approximate prevailing market rates.

Income taxes

The Company accounts for income taxes under the liability method, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

Earnings (loss) per share

Earnings (loss) per share is presented in accordance with Accounting Standards Update (“ASU”), Earning per Share (Topic 260), which requires the presentation of both basic and diluted earnings per share (“EPS”) on the income statements.

Basic EPS excludes any dilutive effects of options, warrants, and convertible securities but does include the restricted shares of common stock issued. Basic EPS calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year.

Diluted EPS reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Diluted EPS calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

Recently issued accounting pronouncements

In August 2020, FASB issued ASU 2020-06 Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06”), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes separation models for convertible debt that require the convertible debt to be separated into a debt and equity component from US GAAP, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The Company adopted this guidance on January 1, 2023.

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 2 - GOING CONCERN AND LIQUIDITY

As at September 30, 2023, the Company had cash of $nil 0(December 31, 2022 - $2,317). Additionally, as at September 30, 2023, the Company had negative working capital totaling $20,174,374 (December 31, 2022 - $17,325,573) and an accumulated deficit of $98,551,864 (December 31, 2022 - $94,695,339).

These financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Based on current financial projections, the Company does not have sufficient existing cash resources to fund its current limited operations. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern.

It is the Company’s intention to incur debt and/or raise additional funding through equity financing to fund ongoing operating expenses. There is no assurance that these events will be satisfactorily completed or at terms acceptable to the Company. Any issuance of equity securities, if accomplished, could cause substantial dilution to existing stockholders. Any failure by the Company to successfully implement these plans would have a material adverse effect on its business, including the possible inability to continue operations.

NOTE 3 - INVESTMENT

As at September 30, 2023, the balance of investments was $nil 0(December 31, 2022 - $78,760).

During the three months ended March 31, 2023, the Company determined that its investment in Klonetics, Inc., consisting of 83,333 Class A common shares purchased on October 6, 2020 at $0.60 CAD per share and 83,333 Class A common shares purchased on January 15, 2021 at $0.60 CAD per share had no value and impaired the value of the investment to $nil. As a result, the Company recorded a loss on investment of $78,760 for the three months ended March 31, 2023.

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable are recognized initially at the transaction price and subsequently measured at the undiscounted amount of cash or other consideration expected to be paid. Accrued expenses are recognized based on the expected amount required to settle the obligation or liability.

A summary of the Company’s accounts payable and accrued liabilities is as follows:


	September 30, 2023		December 31, 2022

Accounts payable and accrued expenses	$	7,772,254	$	6,882,947
Accrued interest (a)		405,356		151,925
Accrued legal settlement (b)		190,000		190,000
Total accounts payable and accrued liabilities	$	8,367,610	$	7,224,872

(a)	Represents interest accrued on the outstanding convertible notes and other notes - (see Note 5, Note 6, and Note 11).

(b)	The Company had previously been a party to an action filed by Gary M. Cohen, a former officer and director of the Company in 2014. In March 2015, the Company entered into a settlement agreement with Mr. Cohen wherein the Company agreed to repurchase 2,250,000 shares of its common stock from Mr. Cohen in consideration for $350,000. Mr. Cohen passed away while there was a remaining balance of $190,000 remaining to be paid in accordance with the settlement agreement. The Company has taken the position that his death has discharged any obligation the Company might have to make the balance of the payments. The Company has not received any demand for payment or otherwise been involved in any attempt to collect this balance for a period of greater than two years prior to the date of this Report.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 5 - RELATED PARTY TRANSACTIONS

A summary of the Company’s related party liabilities is as follows:

Schedule of related party liabilities
	September 30, 2023		December 31, 2022

Loan payable - related party	$	1,519,018	$	74,497
Liability for right-of-use building, current portion		187,793		260,432
Liability for right-of-use building		5,557,272		5,333,045
Total loan payable, related parties	$	7,264,083	$	5,667,974

The loan payable to related parties is comprised of a $27,867 interest-free loan from the Company's former CEO and a $692,239 promissory note from a shareholder of the Company and principal of Koze Investments, LLC (“Koze”) whereby on May 25, 2023, Koze agreed to advance up to $2,000,000 to the Company in funding to pay for certain documented Company expenses. The promissory note with Koze bears interest at 24% compounded monthly. As at September 30, 2023, the accrued interest on the promissory note amounted to $42,699.

Effective January 1, 2022, the Company entered into a lease agreement with Formosa Mountain Ltd., whose principal shareholder is also the principal shareholder of Koze, to lease a cannabis production facility in Cremona, Alberta, Canada. The facility is a 55,000 square foot, 6,000 kg per year plant, built in 2015. The lease payments are $82,500 CAD per month increasing by 5% each year. The lease has a 20-year term. As at September 30, 2023, the Company was in arrears by $1,769,625 CAD (December 31, 2022 - $990,000) on its monthly lease payment. The amount in arrears is included in accounts payable and accrued liabilities (Note 4).

Effective February 1, 2023, the Company entered into a lease agreement to lease one office at 520 - 5th Avenue SW, Calgary, Alberta, Canada, T2P 3R7. The rent is $500 CAD per month. This space was provided by a company to which Mr. Orman, one of the Company’s directors, serves as a director. During the three and nine months ended September 30, 2023, the Company incurred rent expense in total of $nil 0and $2,615, respectively.

NOTE 6 - CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

A continuity of the Company’s convertible notes is as follows:


Balance, December 31, 2021	$	943,017
Proceeds received		912,952
Value of convertible notes converted to 97,646,062 common shares		(552,517	)
Note discount		(162,392	)
Balance, net of note discount, December 31, 2022		1,141,060
Add back:Note discount		162,392
Balance, December 31, 2022		1,303,452
Proceeds received		213,750
Value of conversion of notes to 26,717,553 common shares		(137,950	)
Balance, September 30, 2023	$	1,379,252

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 6 - CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (continued)

During the three and nine months ended September 30, 2023, the Company recorded a loss on conversion of $nil (2022 - $421,986) and $429,471 (2022 - $713,786), respectively; recorded $39,219 (2022 - $74,497) and $113,529 (2022 - $118,396), respectively, in interest expense on its convertible notes; and amortized $nil (2022 - $166,594) and $162,392 (2022 - $383,543), respectively, of note discount which was charged to interest expense.

As at September 30, 2023, the Company had $ 271,076 (December 31, 2022 - $151,925) in accrued interest on these notes, recorded in accounts payable and accrued liabilities, and $nil (December 31, 2022 - $162,932) in unamortized note discount related to these notes.

As at the date of this Report, all convertible notes were past their maturity date. Additionally, as a result of the late filing of previous Reports, and the loss of the Company’s active listing in the OTC market, the penalty provisions of all convertible notes outstanding became effective. The Company estimated that the maximum penalty provisions amounted to one times the face value of all convertible notes outstanding and recorded an accrued liability for penalties amounting to $1,303,452, which has been recorded in accounts payable and accrued liabilities.

As at September 30, 2023 the Company had derivative liabilities of $ 906,946 (December 31, 2022 - $1,008,868).

A summary of the Company’s assumption used in the Black-Scholes option pricing model for derivative liabilities valuation as at September 30, 2023 is as follows:


	September 30, 2023
Exercise Price		$0.0025-$0.0105
Stock Price	$	0.014
Risk-free interest rate		4.83%
Expected volatility		177.50%
Expected life (in years)		1.0
Expected dividend yield		0.00%
Fair Value	$	906,946

The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility of its common stock. The expected life of the conversion feature of the notes was based on the remaining term of the notes. The expected dividend yield was based on the fact that the Company has not customarily paid dividends in the past and does not expect to pay dividends in the future.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 7 - NOTES PAYABLE

A summary of the Company’s notes payable is as follows:

Schedule of notes payable
	September 30, 2023		December 31, 2022

Promissory notes (ASM)	$	7,534,889	$	7,382,998
CEBA Loan		44,379		44,300
Promissory notes (secured investors)		288,560		288,560
Total notes payable	$	7,867,828	$	7,715,858

Pursuant to the terms of a securities purchase agreement with Alternative Medical Solutions, Inc. (“AMS”), entered into on December 31, 2018, the Company issued a non-interest-bearing $7,330,000 ($10,000,000 CAD) promissory note. The promissory note matured on December 31, 2021, and is past due. During the year ended December 31, 2021, the Company recorded $186,610 in amortization expense related to this note discount.

Due to the global COVID 19 outbreak, the Government of Canada introduced the Canada Emergency Business Account (“CEBA”) program. CEBA provided an interest free loan (“CEBA Loan”) of up to $60,000 CAD to eligible businesses. On September 14, 2023, the Government of Canada announced changes to the maturity date of the CEBA Loan, which was extended to December 31, 2026. The loan will remain interest-free until January 18, 2024 with a rate of 5% per annum being applied from January 19, 2024. Repayment of $40,000 CAD by January 18, 2024 will result in a $20,000 CAD loan forgiveness. Should the CEBA Loan remain outstanding on January 18, 2023, it will convert to a non-amortizing term loan with the full principal repayment due on December 31, 2026. The Company received the full $60,000 CAD loan amount and as at September 30, 2023 and December 31, 2022 the Company’s CEBA Loan balance is $44,379 ($60,000 CAD) and $44,300 ($60,000 CAD), respectively.

During the year ended December 31, 2021, the Company entered into promissory note agreements with secured investors for non-interest-bearing notes maturing within 12 months with a total value of $238,560 ($300,000 CAD). These notes are secured by a general security agreement over all present and after acquired property, assets, and undertakings. As at September 30, 2023 and December 31, 2022, the notes are past due and owing in the amount of $238,560 ($300,000 CAD) and $238,560 ($300,000 CAD), respectively.

NOTE 8 - INCOME TAXES

As at December 31, 2022, the Company had approximately $98,000,000 of federal net operating loss carryforwards (“NOLS”) in the United States. The federal net operating loss carryforwards begin to expire in 2030. State net operating loss carryforwards begin to expire in 2034. Due to the change in ownership provisions of the Internal Revenue Code, the availability of the Company’s net operating loss carryforwards could be subject to annual limitations against taxable income in future periods which could substantially limit the eventual utilization of such carryforwards. The Company has not analyzed the historical or potential impact of its equity financings on beneficial ownership and therefore no determination has been made whether the net operating loss carryforward is subject to any Internal Revenue Code Section 382 limitation. To the extent there is a limitation there could be a substantial reduction in the deferred tax asset with an offsetting reduction in the valuation allowance. As at September 30, 2023, the Company has no unrecognized income tax benefits (December 31, 2022 - $nil).

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 8 - INCOME TAXES (continued)

The tax years from 2014 and forward remain open to examination by federal and state authorities due to net operating loss and credit carryforwards. The Company is currently not under examination by the Internal Revenue Service or any other taxing authorities. Since the company has never been profitable, the Company has established a full valuation allowance against the deferred tax asset associated with the NOLS.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

Effective February 1, 2023, the Company entered into a lease agreement to lease one office at 520 - 5^th Avenue SW, Calgary, Alberta, Canada, T2P 3R7. The rent is $500 CAD per month. This space was provided by a company to which Mr. Orman, one of the Company’s directors, serves as a director.

NOTE 10 - STOCKHOLDERS’ EQUITY

Preferred stock

The Company is authorized to issue up to 3,100,000 shares of one or more series of preferred stock at a par value of $0.0001 per share. The Board of Directors may, without stockholder approval, determine the dividend rates, redemption prices, preferences on liquidation or dissolution, conversion rights, voting rights, and any other preferences.

Series A preferred stock

In April 2018, the Company issued 60,000 shares of its series A convertible preferred stock (“Series A Stock”) for $1.00 per share to certain investors who then became members of management and the Board of Directors. Each share of Series A Stock is not redeemable, entitles the holder to 1,250 votes on all matters submitted to a vote of the shareholders; is convertible into 1,250 shares of common stock and each vote is on an as-converted basis. In addition, the holders of outstanding Series A Stock will only be entitled to receive dividends upon declaration by the Board of Directors of a dividend payable on the Company’s common stock, whereupon the holders of the Series A Stock will receive a dividend on the number of shares of common stock into which each share of Series A Stock is convertible.

The beneficial conversion feature (“BCF”) attributed to the purchase of Series A Stock was deemed to have no value on the date of purchase because there was no public trading market for the Series A Stock, and none is expected to develop in the future. Therefore, the BCF related to the Series A Stock was considered to have no value on the date of issuance.

As at September 30, 2023, 84,416 (December 31, 2022 - 84,416) shares of Series A Stock were issued and outstanding.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 10 - STOCKHOLDERS’ EQUITY (continued)

Series B preferred stock

In August 2019, the Company closed an offering of up to $3 million of units at a price of $1.00 per unit. Each unit consisted of one share of series B convertible preferred stock (“Series B Stock”) and one common stock purchase warrant (“Common Warrant”) with no expiry date. Each Series B Stock is convertible into one share of the Company’s common stock at the election of the holder. Each Common Warrant is exercisable to purchase one share of common stock at the election of the holder at an exercise price of $2.00 per share, which offering is to be offered only to “accredited investors,” as that term is defined in Rule 501 of Regulation D of the Securities and Exchange Commission regulations. As at December 31, 2020, the Company had accepted $475,000 in subscriptions in this offering.

As at September 30, 2023, 2,455,000 (December 31, 2022 - 2,475,000) shares of Series B Stock and Common Warrants were issued and outstanding.

Common stock

The Company is authorized to issue 5,000,000,000 shares of common stock at a par value $0.0001 per share. As at September 30, 2023, 294,764,614 (December 31, 2022 - 274,124,622) shares of common stock were issued and outstanding.

Stock purchase warrants

A summary of the Company’s number of stock purchase warrants outstanding and exercisable for period ended September 30, 2023 is as follows:

Schedule of stock purchase warrants
	Number of stock purchase warrants		Weighted average exercise price		Weighted average remaining life
July 1, 2024	$	1,019,750	$	1.33		0.75

There was no warrant activity during the periods ended September 30, 2023 and December 31, 2022.

During the three and nine months ended September 30, 2023, the Company recorded $45,245 (2022 - $45,245) and $135,734 (2022 - $135,734), respectively, in stock-based compensation related to issued warrants being recognized over a five-year period.

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 10 - STOCKHOLDERS’ EQUITY (continued)

A summary of the Company’s assumptions used in the Black-Scholes pricing model for valuation of stock purchase warrants for the periods ended September 30, 2023 and December 31, 2022 are as follows:


Expected dividend yield (1)			0.00%
Risk-free interest rate (2)			0.07%
Volatility			135%
Expected life in years			5.00

(1)	The Company has no history or expectation of paying cash dividends on its Common Stock.
(2)	The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.

NOTE 11 - RIGHT-OF-USE ASSETS

A summary of the Company’s right-of-use assets as at September 30, 2023 is as follows:

Schedule of right of use assets
	Gross Carrying Amount		Accumulated Depreciation			Net Book Value
Right-of-use buildings	$	5,407,330	$	(473,142	)	$	4,934,188

A summary of the Company’s right-of-use assets as at December 31, 2022 is as follows:

		Gross Carrying Amount				Accumulated Depreciation				Net Book Value
Right-of-use buildings		$	5,397,497			$	(269,875	)		$	5,127,622

As at September 30, 2023, the weighted average remaining lease term is 18.25 years (December 31, 2022 - 19 years) and the weighted average discount rate is 16.9% (2022 - 16.9%).

CANNAPHARMARX, INC.

NOTES TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022

NOTE 11 - RIGHT-OF-USE ASSETS (continued)

Supplementary information on the Company’s lease liabilities as at September 30, 2023 and 2022 included the following:

Schedule of lease liabilities
	September 30, 2023		September 30, 2022
Interest	$	721,451	$	717,929
Amortization and depreciation		203,737		209,976
Finance lease related expenses	$	925,188	$	927,905

Finance lease related payments	$	579,382	$	568,689

Future lease payments under the Company’s non-cancellable finance leases as at September 30, 2023 were as follows:


2023	$	192,215
2024		807,506
2025		847,775
2026		890,166
2027		932,556
2028		979,012
Thereafter		18,208,278
Total undiscounted cash flows	$	22,857,508
Imputed interest		(17,112,442	)
Liability for right-of-use building, total	$	5,745,066
Liability for right-of-use building, current portion		187,793
Liability for right-of-use building		5,557,272

NOTE 12 - SUBSEQUENT EVENTS

On October 16, 2023, the Company issued 14,456,522 common shares to Diagonal Lending, LLC to retire $13,300 of convertible debt.

On October 18, 2023, the Company issued 14,615,000 common shares to Janbella Group, LLC to retire $7,288 of convertible debt.

On November 6, 2023, the Company issued 16,000,000 common shares to Diagonal Lending, LLC to retire $15,680 of convertible debt.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of the Company’s financial condition and results of operations should be read together with the Company’s financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and related footnotes included in our Transition Report on Form 10-K for the year ended December 31, 2022.

In connection with, and because we desire to take advantage of, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward-looking statements in the following discussion and elsewhere in this Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. We disclaim any obligation to update forward looking statements.

Forward-Looking Statements

This Quarterly Report on Form 10-Q includes a number of “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements concerning anticipated financial results and developments of our operations in future periods that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 as filed with the U.S. Securities and Exchange Commission (the “SEC”) on September 9, 2023 any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements. These risks and factors include, by way of example and without limitation:

	·	our ability to successfully commercialize our products and services on a large enough scale to generate profitable operations;
	·	our ability to maintain and develop relationships with customers and suppliers;
	·	our ability to successfully integrate acquired businesses or new brands;
	·	the impact of competitive products and pricing;
	·	supply constraints or difficulties;
	·	the retention and availability of key personnel;
	·	general economic and business conditions;
	·	substantial doubt about our ability to continue as a going concern;
	·	our need to raise additional funds in the future;
	·	our ability to successfully recruit and retain qualified personnel in order to continue our operations;
	·	our ability to successfully implement our business plan;
	·	our ability to successfully acquire, develop or commercialize new products and equipment;
	·	intellectual-property claims brought by third parties; and
	·	the impact of any industry regulation.

This list is not exhaustive of the factors that may affect the Company’s forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Except as required by law, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. The Company qualifies all the forward-looking statements contained in this Quarterly Report on Form 10-Q by the foregoing cautionary statements.

During the three and nine months ended September 30, 2023 the Company had no revenues from operations. Loss from operations for the three and nine months ended September 30, 2023 was $667,497 (2022 - $588,475) and 2,280,713 (2022 - $2,008,173), respectively. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Readers are urged to carefully review and consider the various disclosures made by us in this Report and in our other reports filed with the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

As used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms “CannaPharmaRX”, CANNAPHARMARX”, the “Company”, “we”, “us”, and “our” refer to CannaPharmaRX, Inc. and our wholly owned subsidiaries. Unless otherwise specified, all dollar amounts are expressed in United States dollars (“USD”).

OVERVIEW AND HISTORY

The Company was originally incorporated in the State of Colorado in August 1998 under the name Network Acquisitions, Inc. and changed its name to Cavion Technologies, Inc. (“Cavion”) in February 1999.

On December 21, 2000, Cavion filed for protection under Chapter 11 of the United States Bankruptcy Code. In connection with the filing, on February 16, 2001, Cavion sold its entire business, and all of its assets, for the benefit of its creditors. Subsequent to the sale, Cavion retained liabilities of approximately $8.4 million and were dismissed by the Court from the Chapter 11 reorganization, effective March 13, 2001, at which time the last of Cavion’s remaining directors resigned.

In October 2006, the Company changed its name to Concord Ventures, Inc. (“Concord”) and in February 2008, was re-listed on the OTC Bulletin Board.

In April 2010, Concord re-domiciled in Delaware under the name CCVG, Inc. (“CCVG”). Effective December 31, 2010, CCVG completed an Agreement and Plan of Merger and Reorganization (the “Reorganization") which provided for the merger of two of our wholly owned subsidiaries, resulting in a name change to Golden Dragon, Inc. (“Golden Dragon”). Golden Dragon was the surviving publicly quoted parent holding company.

On May 9, 2014, Golden Dragon entered into a Share Purchase Agreement with CannaPharmaRX, Inc., a Colorado corporation (“Canna Colorado”), and David Cutler, a former President, Chief Executive Officer, Chief Financial Officer, and director of Golden Dragon. Under the Share Purchase Agreement, Canna Colorado purchased 1,421,120 shares of Golden Dragon common stock from Mr. Cutler and an additional 9,000,000 restricted common shares directly from Golden Dragon.

On May 15, 2014, as amended and effective January 29, 2015, we entered into an Agreement and Plan of Merger (the “Merger”) pursuant to which Canna Colorado became a subsidiary of Golden Dragon. In October 2014, Golden Dragon changed its legal name to CannaPharmaRX, Inc. (“CPRX”). Pursuant to the Merger, all shares of the former Golden Dragon common stock previously owned by Canna Colorado were canceled. As a result of the transactions disclosed above, CPRX became an early-stage pharmaceutical company whose purpose was to advance cannabinoid research and discovery using proprietary formulation and drug delivery technology then under development.

In April 2016, CPRX ceased operations and the Company’s management resigned their respective positions with the Company, with the exception of Mr. Gary Herick, who remained an officer and director until March 2019.

Effective December 31, 2018, CPRX and Hanover CPMD Acquisition Corp. (“CPMD Hanover”) a newly formed, wholly owned subsidiary, entered into a Securities Purchase Agreement with Alternative Medical Solutions, Inc. (“AMS”), an Ontario, Canada corporation organized under the laws of the Province of Ontario, Canada and its shareholders, wherein the Company acquired all of the issued and outstanding securities of AMS. As a result of the completion of the acquisition of AMS on December 31, 2019, the Company no longer fit the definition of a “shell company,” as defined in Rule 405 of the Securities Act and Rule 12b-2 of the Exchange Act, and filed the required disclosure on Form 8-K/A with the SEC on February 14, 2019, advising that it was no longer a shell company pursuant to the aforesaid Rule.

Effective February 25, 2019, the Company acquired 3,936,500 shares and 2,500,000 Warrants to purchase 2,500,000 shares of Common Stock of GN Ventures, Ltd. (“GN”), formerly known as Great Northern Cannabis, Ltd., in exchange for an aggregate of 7,988,963 shares of its Common Stock, from a former shareholder of GN. While no assurances can be provided, the Company believes this is the initial step in its efforts to acquire all or a significant portion of the issued and outstanding stock of GN. In May 2020, the Company exchanged 5,507,400 of its shares for 3,671,597 shares of GN.

GN owns a 60,000 square foot cannabis cultivation and grow facility located on 38 acres in Stevensville, Ontario, Canada (“the Stevensville Facility”). Because the Company is a minority shareholder of GN and GN is a privately held company, the Company cannot confirm that the information it currently has on GN’s operations is complete or fully reliable. GN estimates annual total production capacity from the Stevensville Facility of up to 12,500 kilograms of cannabis. Once completed, the Stevensville Facility and GN’s subsidiary, 9869247 Canada Limited, received a license to cultivate from the Canadian Ministry of Health on July 5, 2019. As a result, in October 2019, GN commenced cultivation activities and began generating revenues during the first calendar quarter of 2020.

Effective June 11, 2019, the Company entered into a Securities Purchase Agreement with Sunniva, Inc. (“Sunniva”), a British Columbia, Canada corporation wherein the Company agreed to acquire all of the issued and outstanding securities of Sunniva’s wholly-owned subsidiaries Sunniva Medical Inc. (“SMI”) and 1167025 B.C. LTD (“1167025”) for approximately $16.0 million Canadian dollars (“CAD”) in cash and a promissory note in the principal amount of $4.0 million CAD. These companies own the Sunniva Canada Campus, which includes construction assets for a planned 759,000 square-foot greenhouse located on an approximately 114-acre property in Okanagan Falls, British Columbia, Canada.

On June 8, 2020, the Company received a notice of termination of this Purchase Agreement from Sunniva. As a result, the Company incurred a charge of $1,881,126 due to the write-off of its deposit to Sunniva, banking fees and prepaid expenses associated with the failed acquisition of Sunniva expenses. The accompanying financial statements as at September 30, 2023, do not reflect potential recovery amounts related to Sunniva and other parties, if any.

On January 6, 2021, the Company executed an Agreement of Purchase and Sale through its wholly owned subsidiary, AMS for the sale of the lands and premises located at Hanover, Ontario, Canada for a price was $2,000,000 CAD The facility sold was a 48,750 square foot marijuana grow facility on a 6.7-acre parcel of land located in Hanover, Ontario, Canada. As at the date of the sale, the exterior construction of the building had been completed; however, no interior construction had begun. As a result, and in anticipation of the closing, the Company recorded an impairment of goodwill and fixed assets relating to the property of $7,962,694 at December 31, 2020. This property was security for a $1,000,000 US Note with Koze Investments, LLC (“Koze”) by way of a first ranking charge. The transaction closed on July 9, 2021 and the note with Koze was repaid in full, consisting of principal of $1,000,000 plus accrued interest of $124,735 and penalties of $475,265. The note was discharged accordingly.

On January 6, 2022, the Company entered into a 20-year operating lease with Formosa Mountain Ltd., whose principal shareholder is also the principal shareholder of Koze, to lease a cannabis production facility in Cremona, Alberta, Canada. The facility is a 55,000 square foot plant built in 2015. CPRX recommissioned the facility into a new indoor cannabis farm with 11 growing rooms and 10 drying and packing rooms during 2022. The Company received an Operating License from Health Canada on December 9, 2022, and a Cannabis License from the Canada Revenue Agency on December 22, 2022.

PLAN OF OPERATION

Production and sales from this facility are anticipated in Q4 of 2023, currently pending receipt of Good Agricultural Practices certification from the Israeli Medical Cannabis Agency (commonly referred to as “IMC-GAP certification”). The Company anticipates receipt of this certification before December 31, 2023.

The Company harvested its first crops as planned on August 10 and September 11, 2023, yielding approximately 195kg of saleable cannabis flower product, and anticipates additional harvests on October 21 and November 9, 2023 with comparable yield.

Preliminary discussions with export partners sets conditional per gram pricing at approximately $3.30 CDN/gram. This pricing is based on achieving satisfactory test results associated to tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) content of the dried flower. Expected revenues for both initial harvests, if sold in their entirety, is forecasted at $643,000 CDN. The third and fourth harvest planned in Q4 have similarly forecasted revenues.

The Company’s principal place of business is located at 3600 888-3^rd Street SW, Calgary, Alberta, Canada, phone 949-652-6838; the Company’s website address is www.cannapharmarx.com.

Going Concern

Substantial doubt exists as to CPRX’s ability to continue as a going concern based on the fact that the Company does not have adequate working capital to finance day-to-day operations. The Company did not have any revenues for the three or nine months ended September 30, 2023 and 2022.

The Company’s operating deficit as at September 30, 2023 of $2,280,713 (September 30, 2022 - 2,008,173) indicates substantial uncertainty about the Company’s ability to continue as a going concern. It is the Company’s intention to incur additional debt and/or raise additional funding through equity financing to fund ongoing operating expenses. Management’s ability to implement its plans and continue as a going concern is dependent upon raising additional capital. The Company’s continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to further scale down or perhaps even cease the operation of our business. The issuance of additional equity securities by us could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2023 and 2022

The Company does not currently sell or market any products and did not have any sales for the three months ended September 30, 2023 or 2022.

Cost of goods sold

The Company did not have sales for the three months ended September 30, 2023 or 2022 and, accordingly, there was no cost of goods sold for either period.

Gross profit and gross margin

For the three months ended September 30, 2023 and 2022, the Company had no gross profit or gross margin.

Operating expenses

The Company’s operating expenses consist primarily of general and administrative, payroll and consulting fees, stock-based compensation as well as professional fees associated with the costs for services or employees in finance, accounting, sales, administrative activities and compliance of a public company.

Overall operating expenses in the three months ended September 30, 2023, were $667,497 compared to $588,475 for the three months ended September 30, 2022. The increase of $79,022 in operating expenses in the 2023 period is primarily due to an increase of approximately $134,802 in general and administrative expenses, partially offset by a decrease of $52,238 in professional fees.

Other income (expenses)

Other income was $103,129 for the three months ended September 30, 2023, compared to other expenses of $724,773 for the three months ended September 30, 2022. The increase of $827,902 in other income/expenses in 2023 is primarily attributable to an increase of $537,961 in the fair value of derivative liability, an increase in the loss on the extinguishment of debt to $nil from the 2022 loss of $203,130, and a decrease in loss on investments of $86,811.

Net loss

During the three months ended September 30, 2023, the Company incurred a net loss of $564,368 (2022 - $1,313,248).

RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 and 2022

The Company does not currently sell or market any products and did not have any sales for the nine months ended September 30, 2023 or 2022.

Cost of goods sold

The Company did not have sales for the nine months ended September 30, 2023 or 2022 and, accordingly, there was no cost of goods sold for either period.

Gross profit and gross margin

For the nine months ended September 30, 2023 and 2022, the Company had no gross profit or gross margin.

Operating expenses

Overall operating expenses in nine months ended September 30, 2023, were $2,280,713 compared to $2,008,173 for the nine months ended September 30, 2022. The increase of $272,540 in operating expenses in the 2023 period is primarily due to an increase of approximately $346,506 in general and administrative as well as an increase of approximately $131,546 in payroll and consulting fees due to activity at the Cremora facility, partially offset by a decrease of $197,965 in professional fees.

Other income (expenses)

Other expenses were $1,575,812 for the nine months ended September 30, 2023, compared to $2,883,386 for the nine months ended September 30, 2022. The decrease of $1,307,574 in other expenses in the current period is primarily attributable to the change in the fair value of derivative liability of $828,317, a decrease in the loss on the extinguishment of debt of $284,315, and a decrease in interest expense of $273,702 due primarily to fluctuating CAD/USD foreign exchange rates, partially offset by an increase of loss of investments in the current period of $78,760.

Net loss

During the nine months ended September 30, 2023, the Company incurred a net loss of $3,856,525 (2022 - $4,891,559).

LIQUIDITY AND CAPITAL RESOURCES

As at September 30, 2023, the Company had cash and cash equivalents of $nil (December 31, 2022 - $2,317).

Cash flows from operating activities

During the nine months ended September 30, 2023, the Company used $970,032 (2022 - $356,894) in operating activities. The difference in cash used in operating activities is attributable to changes in operating assets and liabilities in 2023 compared to 2022.

Cash flows from investing activities

During the nine months ended September 30, 2023, the Company used $78,880 (2022 - $106,886) in investing activities. The difference is attributable to a reduce in purchasing of property, plant and equipment in 2023 compared to 2022.

Cash flows from financing activities

During the nine months ended September 30, 2023, $1,046,595 (2022 - $443,515) was provided from financing activities. The difference in cash provided from financing activities is attributable to the issuance of convertible notes and proceeds from loans with related parties, offset by payments to Formosa Mountain Ltd. to lease a cannabis production facility in Cremona, Alberta, Canada.

In general, based on historical losses, the Company will be required to continue raising operating capital through debt and equity.

Currently, the Company has no committed source for any funds to allow completion of any of our proposed acquisitions or projects in progress. No representation is made that any funds will be available when needed. In the event funds cannot be raised as required, we may not be able to carry out our business plan. Our inability to obtain funding for our projects will have a negative impact on our anticipated results of operations.

Inflation

Although our operations are influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine-month period ended September 30, 2023.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The Company is classified as a smaller reporting company and is not required to provide the information under this item pursuant to Regulation S-K.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures - Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as at the end of the period covered by this Report.

These controls are designed to ensure that information required to be disclosed in the reports we file or submit pursuant to the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. As a result of the late filing of our December 31, 2022 Form 10-K and March 31, 2023 and June 30, 2023 10-Qs, our common stock was downgraded by the OTC Markets Group to the “Expert market”.

Based on this evaluation, and evidenced by our late filings, our CEO and CFO concluded that our disclosure controls and procedures were not effective as at June 30, 2023 at the reasonable assurance level. We have implemented new procedures for the period ended September 30, 2023 to mitigate this ineffectiveness and believe that, given our timely filing of this Report, the newly implemented disclosure procedures were effective as at September 30, 023. We believe that our financial statements presented in this Form 10-Q fairly present, in all material respects, our financial position, results of operations, and cash flows for all periods presented herein.

Inherent Limitations - Our management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdown can occur because of simple error or mistake. In particular, many of our current processes rely upon manual reviews and processes to ensure that neither human error nor system weakness has resulted in erroneous reporting of financial data.

Changes in Internal Control over Financial Reporting - Other than an emphasis on timely filing, there were no changes in our internal control over financial reporting during the period ended September 30, 2023, which were identified in conjunction with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As part of our acquisition of AMS, we assumed an action filed against AMS by Ataraxia Canada, Inc. (“Ataraxia”), alleging breach of contract, specifically, breach of a non-binding term sheet providing for Ataraxia to acquire controlling interest in AMS. Ataraxia is seeking $15 million in damages. A Statement of Claim was prepared by Ataraxia, as plaintiff, and circulated to AMS, as defendant, on August 2, 2018, under the Ontario Superior Court of Justice (Court file no. CV-17-580157). The parties have engaged in discussions with respect to a potential settlement of this matter. Counsel has advised that it believes it is premature to speculate on any outcome of this litigation, including the likelihood of a settlement or any potential liability at this time.

Our agreement to acquire AMS contained a provision requiring us to diligently defend against the claims brought forth in, and assume full and complete control of, the Ataraxia litigation, provided that we shall not enter into any compromise or settlement in respect of the Ataraxia litigation without the prior written consent of the sellers, which consent is not to be unreasonably withheld, conditioned or delayed. The sellers are obligated to cooperate fully and make available to us all pertinent information and witnesses under their control, make such assignments and take such other steps as in the opinion of our counsel are reasonably necessary to enable us to defend against the claims brought forth in the Ataraxia litigation.

We are currently reviewing two separate situations with our legal counsel in order to ascertain whether we have claims against Steven Barber arising out of his default of the Consulting Agreement we entered into as part of the AMS acquisition more fully described in” Part I, Item 1,” Business, above and various claims against Gary Herick, a former officer and director. In January 2020, we received correspondence from counsel for Mr. Barber demanding payment on amounts purported to be due pursuant to his Consulting Agreement with us. We are currently reviewing whether Mr. Barber has performed pursuant to the terms of the Consulting Agreement.

No decision on whether to proceed on either of these situations has been reached as at the date of this Report.

On April 15, 2021, Bristol Capital Investors, LLC (BCI) filed a lawsuit in the Superior Court of the State of California, County of Los Angeles against CannaPharmaRX Inc. and Does 1 - 50, inclusive (Case No. 21^st CV1 3696). The lawsuit alleges that CPRX breached the Amended and Restated Limited Liability Company Membership Purchase Agreement it had entered into with Bristol Capital Investors, LLC (BCI) to purchase BCI’s interest in Ramon Road Production Campus, LLC (RRPC), a single asset entity which owned an improved property, known as the Glass House, located in Cathedral City, California. BCI alleges causes of action for Fraud, Breach of Contract, Breach of the Implied Covenant of Good Faith and Fair Dealing, and Negligent Misrepresentation, and seeks compensatory and consequential damages in the amount of $10.5 million dollars plus attorneys’ fees and costs. CPMD intends to vigorously defend against BCI’s lawsuit, going forward. The parties conducted a court-ordered mediation, and the parties are engaging in on-going discussions.

We are not a party to any other legal proceeding or aware of any other threatened action as at the date of this Report.

ITEM 1A. RISK FACTORS

We are a smaller reporting company and are not required to provide the information under this item pursuant to Regulation S-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the nine months ended September 30, 2023, the Company issued 20,619,992 common shares pursuant to conversions of convertible debt to common stock. The Company also exchanged 20,000 shares of Preferred B Stock for 20,000 shares of common stock, and cancelled 6,097,561 common stock.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURE

Not Applicable

ITEM 5. OTHER INFORMATION

None

ITEM 6. EXHIBITS

Exhibit No.		Description

31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted in IXBRL, and included in exhibit 101).

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on November 17, 2023.

	CannaPharmaRx, Inc.


	By:	/s/ Dean Medwid
		Dean Medwid,
		Principal Executive Officer


	By:	/s/ Oliver Foeste
		Oliver Foeste, Principal Financial Officer

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Dean Medwid, certify that:

I have reviewed this quarterly report on Form 10-Q of CannaPharmaRx, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 17, 2023

/s/ Dean Medwid

Dean Medwid, Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

I, Oliver Foeste, certify that:

I have reviewed this quarterly report on Form 10-Q of CannaPharmaRx, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 17, 2023

/s/ Oliver Foeste

Oliver Foeste, Chief Financial Officer (Principal Financial Officer)

Exhibit 32

CERTIFICATION PURSUANT TO

18 USC, SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report of CannaPharmaRx Inc. (the “Company”) on Form 10-Q for the three month period ended September 30, 2023, as filed with the Securities and Exchange Commission on November 16, 2023 (the “Report”), we, the undersigned, in the capacities and on the date indicated below, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

The Report fully complies with the requirements of Rule 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 17, 2023

/s/ Dean Medwid

Dean Medwid, Chief Executive Officer (Principal Executive Officer)

Dated: November 17, 2023

/s/ Oliver Foeste

Oliver Foeste, Chief Financial Officer (Principal Financial Officer)

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 16, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	333-251016
Entity Registrant Name	CANNAPHARMARX, INC.
Entity Central Index Key	0001081938
Entity Tax Identification Number	27-4635140
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Suite 3600
Entity Address, Address Line Two	888 – 3rd Street SW
Entity Address, City or Town	Calgary
Entity Address, State or Province	AB
Entity Address, Country	CA
Entity Address, Postal Zip Code	T2P 5C5
City Area Code	949
Local Phone Number	652-6838
Title of 12(b) Security	Common Stock
Trading Symbol	CPMD
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		337,961,136

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (Unaudited) - USD ($)

Sep. 30, 2023

Dec. 31, 2022

Current assets

Cash

$ 0

$ 2,317

HST receivable

54,318

23,251

Prepaid expense

68,539

Other assets

5,907

Total current assets

54,318

100,014

Non-current assets

Property, plant and equipment, net

167,483

107,780

Right-of-use building, net

4,934,188

5,127,622

Investments

78,760

Total assets

5,155,989

5,414,176

Current liabilities

Bank overdraft

245

Accounts payable and accrued liabilities

7,772,254

6,882,947

Accrued interest

^[1]

405,356

151,925

Accrued legal settlement

^[2]

190,000

Notes payable

7,867,828

7,715,858

Convertible notes - net of discount

1,379,252

1,141,060

Derivative liability

906,946

1,008,868

Loan payable - related party

1,519,018

74,497

Liability for right-of-use building, current portion

187,793

260,432

Total current liabilities

20,228,692

17,425,587

Non-current liability

Liability for right-of-use building

5,557,272

5,333,045

Total liabilities

25,785,964

22,758,632

Commitments and contingencies

STOCKHOLDERS’ DEFICIT

Common stock, $0.0001 par value; 5,000,000,000 shares authorized, 294,764,614 and 274,124,622 issued and outstanding as at September 30, 2023 and December 31, 2022, respectively

29,476

27,412

Treasury stock, 6,230,761 and 133,200 shares as at September 30, 2023 and December 31, 2022, respectively

597

(13)

Additional paid-in capital

75,247,742

74,523,642

Accumulated deficit

(98,551,864)

(94,695,339)

Accumulated other comprehensive income

104,658

240,426

Total stockholders’ deficit

(20,629,975)

(17,344,456)

Total liabilities and stockholders’ deficit

5,155,989

5,414,176

Series A Preferred Stock [Member]

STOCKHOLDERS’ DEFICIT

Preferred stock value

84,416

Series B Preferred Stock [Member]

STOCKHOLDERS’ DEFICIT

Preferred stock value

$ 2,455,000

$ 2,475,000

[1]

Represents interest accrued on the outstanding convertible notes and other notes - (see Note 5, Note 6, and Note 11).

[2]

The Company had previously been a party to an action filed by Gary M. Cohen, a former officer and director of the Company in 2014. In March 2015, the Company entered into a settlement agreement with Mr. Cohen wherein the Company agreed to repurchase 2,250,000 shares of its common stock from Mr. Cohen in consideration for $350,000. Mr. Cohen passed away while there was a remaining balance of $190,000 remaining to be paid in accordance with the settlement agreement. The Company has taken the position that his death has discharged any obligation the Company might have to make the balance of the payments. The Company has not received any demand for payment or otherwise been involved in any attempt to collect this balance for a period of greater than two years prior to the date of this Report.

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized	5,000,000,000	5,000,000,000
Common stock, issued	294,764,614	274,124,622
Common stock, outstanding	294,764,614	274,124,622
Treasury stock, Shares	6,230,761	133,200
Series A Preferred Stock [Member]
Preferred shares, par value	$ 1.00	$ 1.00
Preferred shares, authorized	100,000	100,000
Preferred shares, issued	84,416	84,416
Preferred shares, outstanding	84,416	84,416
Series B Preferred Stock [Member]
Preferred shares, par value	$ 1.00	$ 1.00
Preferred shares, authorized	3,000,000	3,000,000
Preferred shares, issued	2,455,000	2,475,000
Preferred shares, outstanding	2,455,000	2,475,000

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses
General and administrative	336,620	201,818	857,573	511,067
Amortization and depreciation	76,550	75,972	223,904	221,589
Stock-based compensation	45,245	45,245	135,734	135,734
Rent	12	3,038	2,615	12,477
Professional fees	44,778	97,016	241,113	439,078
Payroll and consulting fees	164,292	165,386	819,774	688,228
Total operating expenses	667,497	588,475	2,280,713	2,008,173
Loss from operations	(667,497)	(588,475)	(2,280,713)	(2,008,173)
Other income (expenses)
Interest expense	(354,862)	(441,673)	(1,169,502)	(1,443,204)
Loss on the extinguishment of debt	0	(203,130)	(429,471)	(713,786)
Loss on investments	0	0	(78,760)	0
Change in the fair value of derivative liability	457,991	(79,970)	101,921	(726,396)
Total other income (expenses), net	103,129	(724,773)	(1,575,812)	(2,883,386)
Net loss	(564,368)	(1,313,248)	(3,856,525)	(4,891,559)
Foreign currency translation adjustment	33,132	528,940	(135,768)	678,194
Net comprehensive loss	$ (531,236)	$ (784,308)	$ (3,992,293)	$ (4,213,365)

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Basic loss per common share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.02)
Diluted loss per common share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding, Basic	295,096,003	241,098,037	292,670,792	197,052,865
Weighted average number of shares outstanding, Diluted	295,096,003	241,098,037	292,670,792	197,052,865

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities
Net loss	$ (3,856,525)	$ (4,891,559)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	223,904	221,589
Stock-based compensation	135,734	135,734
Interest expense	1,169,502	1,443,204
Loss on extinguishment of debt	429,471	713,786
Loss on investments	78,760	0
Change in the fair value of derivative liability	(101,921)	726,396
Changes in operating assets and liabilities:
HST receivable	(31,067)	(15,233)
Prepaid expenses	68,539	(71,746)
Other assets	5,907	(5,837)
Accounts payable and accrued liabilities	765,295	1,875,820
Cash overdraft	245	0
Accrued interest	142,124	(739,039)
Subscription liability	0	249,991
Net cash used in operating activities	(970,032)	(356,894)
Investing activity
Purchases of property, plant and equipment	(78,880)	(106,886)
Net cash used in investing activity	(78,880)	(106,886)
Financing activities
Proceeds from convertible notes	213,750	694,950
Proceeds from loans payable – related party	1,412,227	74,714
Repayment of promissory notes	0	(596,012)
Proceeds from issuance of Series B preferred shares	0	55,989
Proceeds from issuance of common stock in private placements	0	290,012
Proceeds from commitment shares issued with convertible notes	0	17,000
Proceeds from commitment shares issued for equity line of credit	0	130,000
Proceeds from beneficial conversion feature of convertible notes	0	345,551
Payments made on liability for right-of-use building	(579,382)	(568,689)
Net cash provided by financing activities	1,046,595	443,515
Net change in cash	(2,317)	(20,265)
Cash, beginning of period	2,317	27,767
Cash, end of period	0	7,502
Supplemental disclosure of cash flow information:
Cash paid for interest	0	0
Supplemental disclosure of non-cash flow investing and financing activities:
Acquisition of right-of-use assets for lease obligations	0	5,727,811
Stock issued as a financing expense on convertible notes	0	147,000
Preferred stock issued as a deposit on an acquisition	0	55,989
Common stock issued to convert convertible notes and accrued interest into equity	$ 138,881	$ 1,180,269

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Preferred Stock Series A [Member]	Preferred Stock Series B [Member]	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2021	$ 67,191	$ 475,000	$ 12,551	$ (13)	$ 73,055,579	$ (86,164,319)	$ (371,909)	$ (12,925,920)
Beginning balance, shares at Dec. 31, 2021	67,191	475,000	125,509,810	133,200
Conversion of Series A to common stock	$ (9,011)		$ 1,126		7,885
Conversion of Series A to common stock, shares	(9,011)		11,263,750
Conversion of convertible notes to common stock			$ 2,819		499,096			501,915
Conversion of convertible notes to common stock, shares			28,186,741
Sale of common stock in private placement			$ 250		39,765			40,015
Sale of common stock in private placement, shares			2,500,000
Commitment shares issued with convertible note			$ 100		16,900			17,000
Commitment shares issued with convertible note, shares			1,000,000
Beneficial conversion feature of convertible notes					227,386			227,386
Stock based compensation related to warrant issuances					45,245			45,245
Foreign currency translation adjustment							(120,750)	(120,750)
Net loss						(2,071,982)		(2,071,982)
Ending balance, value at Mar. 31, 2022	$ 58,180	$ 475,000	$ 16,846	$ (13)	73,891,856	(88,236,301)	(492,659)	(14,287,091)
Ending balance, shares at Mar. 31, 2022	58,180	475,000	168,460,301	133,200
Beginning balance, value at Dec. 31, 2021	$ 67,191	$ 475,000	$ 12,551	$ (13)	73,055,579	(86,164,319)	(371,909)	(12,925,920)
Beginning balance, shares at Dec. 31, 2021	67,191	475,000	125,509,810	133,200
Net loss								(4,891,559)
Ending balance, value at Sep. 30, 2022	$ 52,416	$ 2,475,000	$ 25,757	$ (13)	73,211,704	(91,055,878)	306,285	(14,984,729)
Ending balance, shares at Sep. 30, 2022	52,416	2,475,000	257,569,176	133,200
Beginning balance, value at Mar. 31, 2022	$ 58,180	$ 475,000	$ 16,846	$ (13)	73,891,856	(88,236,301)	(492,659)	(14,287,091)
Beginning balance, shares at Mar. 31, 2022	58,180	475,000	168,460,301	133,200
Conversion of convertible notes to common stock			$ 2,398		327,201			329,599
Conversion of convertible notes to common stock, shares			23,987,460
Sale of common stock in private placement			$ 2,500		247,497			249,997
Sale of common stock in private placement, shares			25,000,000
Commitment shares issued for equity line of credit			$ 1,000		129,000			130,000
Commitment shares issued for equity line of credit, shares			10,000,000
Beneficial conversion feature of convertible notes					64,414			64,414
Stock based compensation related to warrant issuances					45,245			45,245
Foreign currency translation adjustment							270,004	270,004
Net loss						(1,506,329)		(1,506,329)
Ending balance, value at Jun. 30, 2022	$ 58,180	$ 475,000	$ 22,744	$ (13)	74,705,213	(89,742,630)	(222,655)	(14,704,161)
Ending balance, shares at Jun. 30, 2022	58,180	475,000	227,447,761	133,200
Conversion of convertible notes to common stock			$ 2,292		346,463			348,755
Conversion of convertible notes to common stock, shares			22,916,415
Conversion of Series A Preferred to common stock	$ (13,764)		$ 1,721		12,044			1
Conversion of Series A Preferred to common stock, shares	(13,764)		17,205,000
Conversion of common shares issued for equity line of credit to Series A Preferred	$ 8,000		$ (1,000)		(7,000)
Conversion of common shares issued for equity line of credit to Series A Preferred, shares	8,000		(10,000,000)
Issuance of Series B Preferred for deposit on acquisition		$ 2,000,000			(1,944,011)			55,989
Issuance of Series B Preferred for deposit on acquisition, shares		2,000,000
Beneficial conversion feature of convertible notes					53,750			53,750
Stock based compensation related to warrant issuances					45,245			45,245
Foreign currency translation adjustment							528,940	528,940
Net loss						(1,313,248)		(1,313,248)
Ending balance, value at Sep. 30, 2022	$ 52,416	$ 2,475,000	$ 25,757	$ (13)	73,211,704	(91,055,878)	306,285	(14,984,729)
Ending balance, shares at Sep. 30, 2022	52,416	2,475,000	257,569,176	133,200
Beginning balance, value at Dec. 31, 2022	$ 84,416	$ 2,475,000	$ 27,412	$ (13)	74,523,642	(94,695,339)	240,426	(17,344,456)
Beginning balance, shares at Dec. 31, 2022	84,416	2,475,000	274,124,622	133,200
Conversion of Series B to common stock		$ (20,000)	$ 2		19,998
Conversion of Series B to common stock, shares		(20,000)	20,000
Conversion of convertible notes to common stock			$ 2,062		504,953			507,015
Conversion of convertible notes to common stock, shares			20,619,992
Stock-based compensation					45,245			45,245
Foreign currency translation adjustment							(5,656)	(5,656)
Net loss						(1,412,573)		(1,412,573)
Ending balance, value at Mar. 31, 2023	$ 84,416	$ 2,455,000	$ 29,476	$ (13)	75,093,838	(96,107,912)	234,770	(18,210,425)
Ending balance, shares at Mar. 31, 2023	84,416	2,455,000	294,764,614	133,200
Beginning balance, value at Dec. 31, 2022	$ 84,416	$ 2,475,000	$ 27,412	$ (13)	74,523,642	(94,695,339)	240,426	(17,344,456)
Beginning balance, shares at Dec. 31, 2022	84,416	2,475,000	274,124,622	133,200
Net loss								(3,856,525)
Ending balance, value at Sep. 30, 2023	$ 84,416	$ 2,455,000	$ 29,476	$ 597	75,247,742	(98,551,864)	104,658	(20,629,975)
Ending balance, shares at Sep. 30, 2023	84,416	2,455,000	294,764,614	6,230,761
Beginning balance, value at Mar. 31, 2023	$ 84,416	$ 2,455,000	$ 29,476	$ (13)	75,093,838	(96,107,912)	234,770	(18,210,425)
Beginning balance, shares at Mar. 31, 2023	84,416	2,455,000	294,764,614	133,200
Conversion of convertible notes to common stock			$ 610		63,415			64,025
Conversion of convertible notes to common stock, shares			6,097,561
Stock-based compensation					45,244			45,244
Foreign currency translation adjustment							(163,244)	(163,244)
Net loss						(1,879,584)		(1,879,584)
Ending balance, value at Jun. 30, 2023	$ 84,416	$ 2,455,000	$ 30,086	$ (13)	75,202,497	(97,987,496)	71,526	(20,143,984)
Ending balance, shares at Jun. 30, 2023	84,416	2,455,000	300,862,175	133,200
Common stock returned to treasury			$ (610)	$ 610
Common stock returned to treasury, shares			(6,097,561)	6,097,561
Stock-based compensation					45,245			45,245
Foreign currency translation adjustment							33,132	33,132
Net loss						(564,368)		(564,368)
Ending balance, value at Sep. 30, 2023	$ 84,416	$ 2,455,000	$ 29,476	$ 597	$ 75,247,742	$ (98,551,864)	$ 104,658	$ (20,629,975)
Ending balance, shares at Sep. 30, 2023	84,416	2,455,000	294,764,614	6,230,761

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

All figures are in United States (“US”) dollars (“USD”) unless indicated otherwise.

Use of estimates

Cash

Comprehensive income or loss

Reclassifications

Certain prior-year amounts have been reclassified to conform to the current-period presentation. These reclassifications had no impact on net earnings and the Company’s financial position.

Leases

Short-term leases (that have an initial term less than 12 months or that are cancellable by the lessor and lessee without significant penalties) are expensed as they are incurred.

Derivative financial instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk.

Foreign currency translation

Harmonized sales tax

Stock-based compensation

Long-lived assets

Fair values of assets and liabilities

Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Financial instruments

Income taxes

Earnings (loss) per share

Recently issued accounting pronouncements

GOING CONCERN AND LIQUIDITY

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN AND LIQUIDITY

NOTE 2 - GOING CONCERN AND LIQUIDITY

INVESTMENT

9 Months Ended

Sep. 30, 2023

Investments, All Other Investments [Abstract]

INVESTMENT

NOTE 3 - INVESTMENT

As at September 30, 2023, the balance of investments was $nil 0(December 31, 2022 - $78,760).

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

A summary of the Company’s accounts payable and accrued liabilities is as follows:


	September 30, 2023		December 31, 2022

Accounts payable and accrued expenses	$	7,772,254	$	6,882,947
Accrued interest (a)		405,356		151,925
Accrued legal settlement (b)		190,000		190,000
Total accounts payable and accrued liabilities	$	8,367,610	$	7,224,872

(a)	Represents interest accrued on the outstanding convertible notes and other notes - (see Note 5, Note 6, and Note 11).

(b)	The Company had previously been a party to an action filed by Gary M. Cohen, a former officer and director of the Company in 2014. In March 2015, the Company entered into a settlement agreement with Mr. Cohen wherein the Company agreed to repurchase 2,250,000 shares of its common stock from Mr. Cohen in consideration for $350,000. Mr. Cohen passed away while there was a remaining balance of $190,000 remaining to be paid in accordance with the settlement agreement. The Company has taken the position that his death has discharged any obligation the Company might have to make the balance of the payments. The Company has not received any demand for payment or otherwise been involved in any attempt to collect this balance for a period of greater than two years prior to the date of this Report.

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2023

RELATED PARTY TRANSACTIONS

NOTE 5 - RELATED PARTY TRANSACTIONS

A summary of the Company’s related party liabilities is as follows:

Schedule of related party liabilities
	September 30, 2023		December 31, 2022

Loan payable - related party	$	1,519,018	$	74,497
Liability for right-of-use building, current portion		187,793		260,432
Liability for right-of-use building		5,557,272		5,333,045
Total loan payable, related parties	$	7,264,083	$	5,667,974

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

NOTE 6 - CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES

A continuity of the Company’s convertible notes is as follows:


Balance, December 31, 2021	$	943,017
Proceeds received		912,952
Value of convertible notes converted to 97,646,062 common shares		(552,517	)
Note discount		(162,392	)
Balance, net of note discount, December 31, 2022		1,141,060
Add back:Note discount		162,392
Balance, December 31, 2022		1,303,452
Proceeds received		213,750
Value of conversion of notes to 26,717,553 common shares		(137,950	)
Balance, September 30, 2023	$	1,379,252

As at September 30, 2023 the Company had derivative liabilities of $ 906,946 (December 31, 2022 - $1,008,868).

A summary of the Company’s assumption used in the Black-Scholes option pricing model for derivative liabilities valuation as at September 30, 2023 is as follows:


	September 30, 2023
Exercise Price		$0.0025-$0.0105
Stock Price	$	0.014
Risk-free interest rate		4.83%
Expected volatility		177.50%
Expected life (in years)		1.0
Expected dividend yield		0.00%
Fair Value	$	906,946

NOTES PAYABLE

9 Months Ended

Sep. 30, 2023

Notes Payable

NOTES PAYABLE

NOTE 7 - NOTES PAYABLE

A summary of the Company’s notes payable is as follows:

Schedule of notes payable
	September 30, 2023		December 31, 2022

Promissory notes (ASM)	$	7,534,889	$	7,382,998
CEBA Loan		44,379		44,300
Promissory notes (secured investors)		288,560		288,560
Total notes payable	$	7,867,828	$	7,715,858

INCOME TAXES

9 Months Ended

Sep. 30, 2023

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 8 - INCOME TAXES

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 9 - COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 10 - STOCKHOLDERS’ EQUITY

Preferred stock

Series A preferred stock

As at September 30, 2023, 84,416 (December 31, 2022 - 84,416) shares of Series A Stock were issued and outstanding.

Series B preferred stock

As at September 30, 2023, 2,455,000 (December 31, 2022 - 2,475,000) shares of Series B Stock and Common Warrants were issued and outstanding.

Common stock

Stock purchase warrants

A summary of the Company’s number of stock purchase warrants outstanding and exercisable for period ended September 30, 2023 is as follows:

Schedule of stock purchase warrants
	Number of stock purchase warrants		Weighted average exercise price		Weighted average remaining life
July 1, 2024	$	1,019,750	$	1.33		0.75

There was no warrant activity during the periods ended September 30, 2023 and December 31, 2022.


Expected dividend yield (1)			0.00%
Risk-free interest rate (2)			0.07%
Volatility			135%
Expected life in years			5.00

(1)	The Company has no history or expectation of paying cash dividends on its Common Stock.
(2)	The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.

RIGHT-OF-USE ASSETS

9 Months Ended

Sep. 30, 2023

Right-of-use Assets

RIGHT-OF-USE ASSETS

NOTE 11 - RIGHT-OF-USE ASSETS

A summary of the Company’s right-of-use assets as at September 30, 2023 is as follows:

Schedule of right of use assets
	Gross Carrying Amount		Accumulated Depreciation			Net Book Value
Right-of-use buildings	$	5,407,330	$	(473,142	)	$	4,934,188

A summary of the Company’s right-of-use assets as at December 31, 2022 is as follows:

		Gross Carrying Amount				Accumulated Depreciation				Net Book Value
Right-of-use buildings		$	5,397,497			$	(269,875	)		$	5,127,622

As at September 30, 2023, the weighted average remaining lease term is 18.25 years (December 31, 2022 - 19 years) and the weighted average discount rate is 16.9% (2022 - 16.9%).

Supplementary information on the Company’s lease liabilities as at September 30, 2023 and 2022 included the following:

Schedule of lease liabilities
	September 30, 2023		September 30, 2022
Interest	$	721,451	$	717,929
Amortization and depreciation		203,737		209,976
Finance lease related expenses	$	925,188	$	927,905

Finance lease related payments	$	579,382	$	568,689

Future lease payments under the Company’s non-cancellable finance leases as at September 30, 2023 were as follows:


2023	$	192,215
2024		807,506
2025		847,775
2026		890,166
2027		932,556
2028		979,012
Thereafter		18,208,278
Total undiscounted cash flows	$	22,857,508
Imputed interest		(17,112,442	)
Liability for right-of-use building, total	$	5,745,066
Liability for right-of-use building, current portion		187,793
Liability for right-of-use building		5,557,272

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 12 - SUBSEQUENT EVENTS

On October 16, 2023, the Company issued 14,456,522 common shares to Diagonal Lending, LLC to retire $13,300 of convertible debt.

On October 18, 2023, the Company issued 14,615,000 common shares to Janbella Group, LLC to retire $7,288 of convertible debt.

On November 6, 2023, the Company issued 16,000,000 common shares to Diagonal Lending, LLC to retire $15,680 of convertible debt.

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

All figures are in United States (“US”) dollars (“USD”) unless indicated otherwise.

Use of estimates

Use of estimates

Cash

Cash

Comprehensive income or loss

Comprehensive income or loss

Reclassifications

Reclassifications

Certain prior-year amounts have been reclassified to conform to the current-period presentation. These reclassifications had no impact on net earnings and the Company’s financial position.

Leases

Leases

Short-term leases (that have an initial term less than 12 months or that are cancellable by the lessor and lessee without significant penalties) are expensed as they are incurred.

Derivative financial instruments

Derivative financial instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risk.

Foreign currency translation

Foreign currency translation

Harmonized sales tax

Harmonized sales tax

Stock-based compensation

Stock-based compensation

Long-lived assets

Long-lived assets

Fair values of assets and liabilities

Fair values of assets and liabilities

Level 1:		Valuation is based on quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities generally include debt and equity securities that are traded in an active exchange market. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2:		Valuation is based on observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. For example, Level 2 assets and liabilities may include debt securities with quoted prices that are traded less frequently than exchange-traded instruments.

Level 3:		Valuation is based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private equity investments and long-term derivative contracts.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Financial instruments

Financial instruments

Income taxes

Income taxes

Earnings (loss) per share

Earnings (loss) per share

Recently issued accounting pronouncements

Recently issued accounting pronouncements

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued liabilities


	September 30, 2023		December 31, 2022

Accounts payable and accrued expenses	$	7,772,254	$	6,882,947
Accrued interest (a)		405,356		151,925
Accrued legal settlement (b)		190,000		190,000
Total accounts payable and accrued liabilities	$	8,367,610	$	7,224,872

(a)	Represents interest accrued on the outstanding convertible notes and other notes - (see Note 5, Note 6, and Note 11).

(b)	The Company had previously been a party to an action filed by Gary M. Cohen, a former officer and director of the Company in 2014. In March 2015, the Company entered into a settlement agreement with Mr. Cohen wherein the Company agreed to repurchase 2,250,000 shares of its common stock from Mr. Cohen in consideration for $350,000. Mr. Cohen passed away while there was a remaining balance of $190,000 remaining to be paid in accordance with the settlement agreement. The Company has taken the position that his death has discharged any obligation the Company might have to make the balance of the payments. The Company has not received any demand for payment or otherwise been involved in any attempt to collect this balance for a period of greater than two years prior to the date of this Report.

RELATED PARTY TRANSACTIONS (Tables)

9 Months Ended

Sep. 30, 2023

Schedule of related party liabilities

Schedule of related party liabilities
	September 30, 2023		December 31, 2022

Loan payable - related party	$	1,519,018	$	74,497
Liability for right-of-use building, current portion		187,793		260,432
Liability for right-of-use building		5,557,272		5,333,045
Total loan payable, related parties	$	7,264,083	$	5,667,974

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of components of convertible debentures


Balance, December 31, 2021	$	943,017
Proceeds received		912,952
Value of convertible notes converted to 97,646,062 common shares		(552,517	)
Note discount		(162,392	)
Balance, net of note discount, December 31, 2022		1,141,060
Add back:Note discount		162,392
Balance, December 31, 2022		1,303,452
Proceeds received		213,750
Value of conversion of notes to 26,717,553 common shares		(137,950	)
Balance, September 30, 2023	$	1,379,252

Schedule of assumption used for derivative liabilities


	September 30, 2023
Exercise Price		$0.0025-$0.0105
Stock Price	$	0.014
Risk-free interest rate		4.83%
Expected volatility		177.50%
Expected life (in years)		1.0
Expected dividend yield		0.00%
Fair Value	$	906,946

NOTES PAYABLE (Tables)

9 Months Ended

Sep. 30, 2023

Notes Payable

Schedule of notes payable

Schedule of notes payable
	September 30, 2023		December 31, 2022

Promissory notes (ASM)	$	7,534,889	$	7,382,998
CEBA Loan		44,379		44,300
Promissory notes (secured investors)		288,560		288,560
Total notes payable	$	7,867,828	$	7,715,858

STOCKHOLDERS’ EQUITY (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of stock purchase warrants

Schedule of stock purchase warrants
	Number of stock purchase warrants		Weighted average exercise price		Weighted average remaining life
July 1, 2024	$	1,019,750	$	1.33		0.75

Schedule of assumptions used for valuation of warrants


Expected dividend yield (1)			0.00%
Risk-free interest rate (2)			0.07%
Volatility			135%
Expected life in years			5.00

(1)	The Company has no history or expectation of paying cash dividends on its Common Stock.
(2)	The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.

RIGHT-OF-USE ASSETS (Tables)

9 Months Ended

Sep. 30, 2023

Right-of-use Assets

Schedule of right of use assets

Schedule of right of use assets
	Gross Carrying Amount		Accumulated Depreciation			Net Book Value
Right-of-use buildings	$	5,407,330	$	(473,142	)	$	4,934,188

A summary of the Company’s right-of-use assets as at December 31, 2022 is as follows:

		Gross Carrying Amount				Accumulated Depreciation				Net Book Value
Right-of-use buildings		$	5,397,497			$	(269,875	)		$	5,127,622

Schedule of lease liabilities

Schedule of lease liabilities
	September 30, 2023		September 30, 2022
Interest	$	721,451	$	717,929
Amortization and depreciation		203,737		209,976
Finance lease related expenses	$	925,188	$	927,905

Finance lease related payments	$	579,382	$	568,689

Schedule of future lease payments under our non-cancellable finance leases


2023	$	192,215
2024		807,506
2025		847,775
2026		890,166
2027		932,556
2028		979,012
Thereafter		18,208,278
Total undiscounted cash flows	$	22,857,508
Imputed interest		(17,112,442	)
Liability for right-of-use building, total	$	5,745,066
Liability for right-of-use building, current portion		187,793
Liability for right-of-use building		5,557,272

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 0	$ 2,317
Derivative liability	$ 906,946	$ 1,008,868

GOING CONCERN AND LIQUIDITY (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 0	$ 2,317
Working capital	20,174,374	17,325,573
Accumulated deficit	$ 98,551,864	$ 94,695,339

INVESTMENT (Details Narrative) - USD ($)			3 Months Ended			9 Months Ended
INVESTMENT (Details Narrative) - USD ($)	Jan. 15, 2021	Oct. 06, 2020	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Investments amount			$ 0			$ 0		$ 78,760
Gain loss on investments			$ 0	$ 78,760	$ 0	$ 78,760	$ 0
Canada, Dollars \| Class A Common Stock [Member] \| Klonetics Plant Inc [Member]
Stock purchased for investment	83,333	83,333

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)

Sep. 30, 2023

Dec. 31, 2022

Payables and Accruals [Abstract]

Accounts payable and accrued expenses

$ 7,772,254

$ 6,882,947

Accrued interest

^[1]

405,356

151,925

Accrued legal settlement

^[2]

190,000

Total accounts payable and accrued liabilities

$ 8,367,610

$ 7,224,872

[1]

Represents interest accrued on the outstanding convertible notes and other notes - (see Note 5, Note 6, and Note 11).

[2]

RELATED PARTY TRANSACTIONS (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Related Party Transactions [Abstract]
Loan payable - related party	$ 1,519,018	$ 74,497
Liability for right-of-use building, current portion	187,793	260,432
Liability for right-of-use building	5,557,272	5,333,045
Total loan payable, related parties	$ 7,264,083	$ 5,667,974

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)			3 Months Ended	9 Months Ended	12 Months Ended
	May 25, 2023	Feb. 01, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Incurred rent expense			$ 0	$ 2,615
Canada, Dollars
Related Party Transaction [Line Items]
Incurred rent expense				1,769,625	$ 990,000
Canada, Dollars \| Mr Orman [Member]
Related Party Transaction [Line Items]
Incurred rent expense		$ 500
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Loans payable	$ 27,867
Interest free loan	692,239
Expenses	$ 2,000,000
Interest rate	24.00%
Accrued interest			$ 42,699	$ 42,699

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Beginning balance	$ 1,303,452	$ 943,017
Proceeds received	$ 213,750	$ 912,952
Debt converted, shares issued	26,717,553	97,646,062
Value of convertible notes converted	$ (137,950)	$ (552,517)
Note discount		(162,392)
Net of note discount, beginning		1,141,060
Add back:Note discount		162,392
Ending balance	$ 1,379,252	$ 1,303,452

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Details 1) - Derivative Liabilities [Member]	9 Months Ended
	Sep. 30, 2023 USD ($)
Offsetting Assets [Line Items]
Derivative liability fair value	$ 906,946
Measurement Input, Exercise Price [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	$0.0025-$0.0105
Measurement Input, Share Price [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	0.014
Measurement Input, Risk Free Interest Rate [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	4.83%
Measurement Input, Price Volatility [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	177.50%
Measurement Input, Expected Term [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	1.0
Measurement Input, Expected Dividend Rate [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	0.00%

CONVERTIBLE NOTES AND DERIVATIVE LIABILITIES (Details Narrative) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Debt Instrument [Line Items]

Loss on conversion of convertible notes

$ 0

$ 421,986

$ 429,471

$ 713,786

Interest expense, debt

39,219

74,497

113,529

118,396

Amortization of debt discount

$ 166,594

162,392

$ 383,543

Accrued interest

^[1]

405,356

$ 151,925

Accrued liabilities

8,367,610

7,224,872

Accrued liability for penalties on convertible notes

1,303,452

Derivative liability

906,946

1,008,868

Convertible Notes [Member]

Debt Instrument [Line Items]

Accrued interest

$ 271,076

151,925

Accrued liabilities

$ 162,932

[1]	Represents interest accrued on the outstanding convertible notes and other notes - (see Note 5, Note 6, and Note 11).

NOTES PAYABLE (Details) - Convertible Debentures [Member] - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Promissory notes (ASM)	$ 7,534,889	$ 7,382,998
CEBA Loan	44,379	44,300
Promissory notes (secured investors)	288,560	288,560
Total notes payable	$ 7,867,828	$ 7,715,858

NOTES PAYABLE (Details Narrative)	3 Months Ended		9 Months Ended		12 Months Ended
NOTES PAYABLE (Details Narrative)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2023 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 CAD ($)	Dec. 31, 2021 CAD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2018 CAD ($)
Debt Instrument [Line Items]
Amortization of note discount	$ 0	$ 166,594	$ 162,392	$ 383,543
C E B A [Member]
Debt Instrument [Line Items]
Notes and Loans, Noncurrent	44,379		44,379			$ 60,000	$ 44,300	$ 60,000
Secured Notes Payable [Member] \| Alternative Medical Solutions [Member]
Debt Instrument [Line Items]
Debt face amount										$ 7,330,000	$ 10,000,000
Amortization of note discount					$ 186,610
Secured Investors [Member]
Debt Instrument [Line Items]
Debt face amount					$ 238,560				$ 300,000
Debt in default	$ 238,560		$ 238,560			$ 300,000	$ 238,560	$ 300,000

INCOME TAXES (Details Narrative) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Net operating loss carryforwards		$ 98,000,000
Unrecognized income tax benefits	$ 0

STOCKHOLDERS' EQUITY (Details)	Sep. 30, 2023 $ / shares shares
Equity [Abstract]
Number of stock purchase warrants \| shares	1,019,750
Weighted average exercise price \| $ / shares	$ 1.33
Weighted average remaining life	9 months

STOCKHOLDERS' EQUITY (Details 1) - Stock Purchase Warrants [Member]	9 Months Ended
	Sep. 30, 2023
Measurement Input, Expected Dividend Rate [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	0.00%
Measurement Input, Risk Free Interest Rate [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	0.07%
Measurement Input, Price Volatility [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	135%
Measurement Input, Expected Term [Member]
Offsetting Assets [Line Items]
Derivatives, determination of fair value	5.00

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Apr. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized	5,000,000,000		5,000,000,000		5,000,000,000
Common stock, par value	$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares issued	294,764,614		294,764,614		274,124,622
Common stock, shares outstanding	294,764,614		294,764,614		274,124,622
Warrants activity	0		0		0
Stock-based compensation related to issued warrants	$ 45,245	$ 45,245	$ 135,734	$ 135,734
Series A Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued	84,416		84,416		84,416	60,000
Preferred stock, par value	$ 1.00		$ 1.00		$ 1.00	$ 1.00
Preferred stock, shares outstanding	84,416		84,416		84,416
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued	2,455,000		2,455,000		2,475,000
Preferred stock, par value	$ 1.00		$ 1.00		$ 1.00
Preferred stock, shares outstanding	2,455,000		2,455,000		2,475,000
Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares issued	3,100,000		3,100,000
Preferred stock, par value	$ 0.0001		$ 0.0001

RIGHT-OF-USE ASSETS (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Right-of-use Assets
Right-of-use buildings gross carrying amount	$ 5,407,330	$ 5,397,497
Right-of-use buildings accumulated depreciation	(473,142)	(269,875)
Right-of-use buildings net book value	$ 4,934,188	$ 5,127,622

RIGHT-OF-USE ASSETS (Details 1) - USD ($)	9 Months Ended
RIGHT-OF-USE ASSETS (Details 1) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Right-of-use Assets
Interest	$ 721,451	$ 717,929
Amortization and depreciation	203,737	209,976
Finance lease related expenses	925,188	927,905
Finance lease related payments	$ 579,382	$ 568,689

RIGHT-OF-USE ASSETS (Details 2) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Right-of-use Assets
2023	$ 192,215
2024	807,506
2025	847,775
2026	890,166
2027	932,556
2028	979,012
Thereafter	18,208,278
Total undiscounted cash flows	22,857,508
Imputed interest	(17,112,442)
Liability for right-of-use building, total	5,745,066
Liability for right-of-use building, current portion	187,793	$ 260,432
Liability for right-of-use building	$ 5,557,272	$ 5,333,045